IP Library Granted Patent US 9,458,216
Granted Patent B2
US 9,458,216 · App. 14/460,563 · Granted Oct 4, 2016

Nucleic acid encoding chimeric IL-1 receptor type I antagonists

Inventors: Thomas M. Barnes (Brookline, MA); Jinzhao Hou (Belmont, MA); Bracken M. King (Boston, MA)
Assignee: ELEVEN BIOTHERAPEUTICS, INC.
C07K14/545A61K38/00C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,458,216
App. No.
14/460,563
Granted
Oct 4, 2016
Kind
B2
Abstract

Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, β strands, and loops from at least two parental cytokines domains.

Claims (29)

1. An isolated nucleic acid comprising a sequence encoding an amino acid sequence at least 95% identical to SEQ ID NO:21.

2. An isolated nucleic acid vector comprising the nucleic acid of claim 1 , wherein the sequence is operably linked to a transcription control sequence.

3. A recombinant host cell comprising a recombinant isolated nucleic acid according to claim 1 .

4. The host cell of claim 3 that is an E. coli host cell.

5. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 7 or fewer substitutions relative to SEQ ID NO:21.

6. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 6 or fewer substitutions relative to SEQ ID NO:21.

7. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 5 or fewer substitutions relative to SEQ ID NO:21.

8. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 4 or fewer substitutions relative to SEQ ID NO:21.

9. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 3 or fewer substitutions relative to SEQ ID NO:21.

10. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 2 or fewer substitutions relative to SEQ ID NO:21.

11. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 1 substitution relative to SEQ ID NO:21.

12. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 7 or fewer non-conservative substitutions relative to SEQ ID NO:21.

13. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 6 or fewer non-conservative substitutions relative to SEQ ID NO:21.

14. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 5 or fewer non-conservative substitutions relative to SEQ ID NO:21.

15. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 4 or fewer non-conservative substitutions relative to SEQ ID NO:21.

16. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 3 or fewer non-conservative substitutions relative to SEQ ID NO:21.

17. The isolated nucleic acid of claim 1 , wherein the amino acid sequence 2 or fewer non-conservative substitutions relative to SEQ ID NO:21.

18. The isolated nucleic acid of claim 1 , wherein the amino acid sequence has 1 non-conservative substitution relative to SEQ ID NO:21.

19. The isolated nucleic acid of claim 1 , wherein the amino acid sequence consists of a single polypeptide chain that is 150-156 amino acids in length.

20. The isolated nucleic acid of claim 1 , further comprising a sequence encoding a hexa-histidine tag.

21. The isolated nucleic acid of claim 1 , wherein the amino acid sequence is at least 98% identical to SEQ ID NO:21.

22. The isolated nucleic acid of claim 1 , further comprising a sequence encoding a hexa-histidine tag.

23. The isolated nucleic acid of claim 1 , consisting of a sequence encoding an amino acid sequence at least 95% identical to SEQ ID NO:21.

24. An isolated nucleic acid comprising a sequence encoding SEQ ID NO:21.

25. An isolated nucleic acid comprising a sequence at least 95% identical to SEQ ID NO:29 and encoding an amino acid sequence at least 95% identical to SEQ ID NO:21.

26. The isolated nucleic acid of claim 25 , wherein the sequence is at least 98% identical to SEQ ID NO:29.

27. The isolated nucleic acid of claim 25 , wherein the sequence is identical to SEQ ID NO:29.

28. An isolated nucleic acid vector comprising the nucleic acid of claim 25 , wherein the sequence is operably linked to a transcription control sequence.

29. A recombinant host cell comprising a recombinant isolated nucleic acid according to claim 25 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2020
From: SESEN BIO, INC.
To: BUZZARD PHARMACEUTICALS AB
Reel/Frame 052758/0220 →
CHANGE OF NAME Recorded May 27, 2020
From: ELEVEN BIOTHERAPEUTICS, INC.
To: SESEN BIO, INC.
Reel/Frame 052758/0304 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2014
From: BARNES, THOMAS M.; HOU, JINZHAO; KING, BRACKEN M.
To: ELEVEN BIOTHERAPEUTICS, INC.
Reel/Frame 033847/0246 →
Continuity (7)
Division 13812582
Provisional Application 61493966 · Jun 6, 2011
Provisional Application 61493967 · Jun 6, 2011
Provisional Application 61436178 · Jan 25, 2011
Provisional Application 61436184 · Jan 25, 2011
Provisional Application 61368799 · Jul 29, 2010
Related Publication 20150087818A1 · Mar 26, 2015